TRIA-001

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTRIA-001
Drug Alias Namedual anti-B-cell maturation antigen/4-1BB bispecific antibody (ABL Bio)dual anti-BCMA/4-1BB bispecific antibody (ABL Bio)dual 4-1BB costimulator/anti-BCMA bispecific antibody (ABL Bio)TRIA-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 stimulantsTumor necrosis factor ligand superfamily member 13 modulators
TargetsTumor necrosis factor ligand superfamily member 13Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsMultiple MyelomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAbl Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAbl Bio IncTrigr Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A